Seeking Alpha
12 Jul 2026, 13:55 UTC · 15w ago
Impact · against what's priced in
BridgeBio's valuation is bolstered by the successful commercial launch of Attruby and a clear regulatory path for infigratinib. The combination of realized Q1 revenue and a multi-billion dollar target market for achondroplasia provides concrete fundamental support for a higher valuation ceiling.
No priced-in read yet
What the story claims
3 claims · scored −1 bearish … +1 bullish
BridgeBio has secured U.S. and international regulatory approvals for acoramidis (Attruby) in ATTR-CM.
More positive than 99% of claims this week
Phase 3 PROPEL 3 data for oral infigratinib in achondroplasia was positive, with an NDA submission planned for Q3 2026 targeting a $2.9B global market.
So whatPositive late-stage data and a clear path to a multi-billion dollar market significantly increase the company's valuation ceiling.
Continue reading
5 related stories
The combination of $180.6 million in Q1 U.S. net revenue for acoramidis and a planned Q3 2026 NDA submission for oral infigratinib targeting a $2.9B market creates significant immediate and forward-looking value.
Read from the article alone
Scored by the NIS engine · methodology.
More positive than 92% of claims this week
Projected U.S. net product revenue for acoramidis reached $180.6 million in Q1 2026.
So whatConcrete revenue figures provide a baseline for fundamental valuation and demonstrate early commercial traction.
More positive than 76% of claims this week
Which stocks this story touches
More positive than 99% of ticker scores this week
Strong Buy rating driven by regulatory approvals, revenue growth, and positive phase 3 clinical data.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
The Motley Fool
12h ago
The Motley Fool
13h ago
−12.7%
Price is moving against the score
$74.95 vs $85.89 close before publication (Jul 10) · not market-adjusted
BBIO chart →
